Beckley Psytech has initiated a Phase IIa study of its 5-MeO-DMT candidate – BPL-003 – for Alcohol Use Disorder (AUD), which will take place at King’s...
While psychedelic research has, to date, largely focused on mathematical modelling and resting-state neuroimaging, cognitive neuroscientists are bringing new rigour to the field through the use...
A group of 13 individuals have become the first people to be licensed to facilitate psilocybin experiences in the United States outside of clinical trials in...
In a recent study, scientists mapped descriptions of psychedelic experiences to the brains of subjects through gene expression analysis of neurotransmitters, in an effort to understand...
Researchers from the Universidade de São Paulo (USP) and ICEERS have found that ayahuasca may modulate neural networks, and suggest that more research is needed to...
Psyched Wellness has carried out a neurobehavioral study evaluating the safety and efficacy of its Amanita Muscaria extract – AME-1.
Enosis Therapeutics, OVID Clinics and the MIND Foundation for Psychedelic Research have joined together to implement the world’s first in-clinic application of Virtual Reality (VR) combined...
Between 1950 and 1965, approximately 40,000 patients were prescribed a form of LSD therapy, as a treatment for neurosis, schizophrenia and psychopathy.
Mind Medicine Australia has provided funding for two studies that will be investigating the use of psilocybin and MDMA.
Justin Townsend, CEO of MycoMeditations, explores what to look for when evaluating a psychedelic retreat if you are considering attending – from what models to consider...